A detailed history of Cibc Private Wealth Group, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cibc Private Wealth Group, LLC holds 6,478 shares of VRTX stock, worth $3.01 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,478
Previous 10,782 39.92%
Holding current value
$3.01 Million
Previous $5.05 Million 40.39%
% of portfolio
0.01%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $1.98 Million - $2.18 Million
-4,304 Reduced 39.92%
6,478 $3.01 Million
Q2 2024

Aug 09, 2024

BUY
$392.81 - $485.53 $3.14 Million - $3.89 Million
8,003 Added 287.98%
10,782 $5.05 Million
Q1 2024

May 10, 2024

SELL
$407.69 - $446.08 $66,453 - $72,711
-163 Reduced 5.54%
2,779 $1.16 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $1.01 Million - $1.21 Million
2,942 New
2,942 $1.2 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $1.92 Million - $2.06 Million
5,690 New
5,690 $1.98 Million
Q2 2023

Nov 21, 2023

BUY
$314.42 - $351.91 $515,019 - $576,428
1,638 New
1,638 $576,000
Q2 2023

Aug 10, 2023

BUY
$314.42 - $351.91 $628 - $703
2 Added 0.12%
1,638 $576,000
Q1 2023

Nov 21, 2023

BUY
$283.23 - $323.1 $463,364 - $528,591
1,636 New
1,636 $515,000
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $463,364 - $528,591
1,636 New
1,636 $515,000
Q4 2022

Jun 01, 2023

BUY
$285.76 - $321.48 $2.52 Million - $2.83 Million
8,816 New
8,816 $2.55 Million
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $2.52 Million - $2.83 Million
8,816 New
8,816 $2.55 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $1.38 Million - $1.54 Million
-5,049 Reduced 55.02%
4,127 $1.2 Million
Q2 2022

Aug 03, 2022

SELL
$234.96 - $292.55 $2.9 Million - $3.61 Million
-12,348 Reduced 57.37%
9,176 $2.59 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $4.21 Million - $4.96 Million
19,011 Added 756.51%
21,524 $5.62 Million
Q4 2021

Feb 08, 2022

BUY
$177.01 - $223.45 $3,717 - $4,692
21 Added 0.84%
2,513 $552,000
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $5.9 Million - $6.6 Million
-32,524 Reduced 92.88%
2,492 $452,000
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $452,225 - $533,293
-2,412 Reduced 6.44%
35,016 $7.06 Million
Q1 2021

May 12, 2021

BUY
$207.02 - $241.31 $1.9 Million - $2.21 Million
9,171 Added 32.46%
37,428 $8.04 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $35.7 Million - $47.6 Million
-172,320 Reduced 85.91%
28,257 $6.68 Million
Q3 2020

Nov 03, 2020

BUY
$255.65 - $303.1 $51.3 Million - $60.8 Million
200,577 New
200,577 $54.6 Million
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $36.5 Million - $47.9 Million
-161,997 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $32.1 Million - $39.8 Million
160,523 Added 10890.3%
161,997 $38.5 Million
Q4 2019

Jan 30, 2020

BUY
$166.71 - $223.91 $245,730 - $330,043
1,474 New
1,474 $323,000
Q3 2019

Oct 16, 2019

SELL
$166.23 - $187.09 $414,743 - $466,789
-2,495 Closed
0 $0
Q2 2019

Jul 31, 2019

BUY
$164.61 - $190.37 $410,701 - $474,973
2,495 New
2,495 $458,000
Q4 2018

Feb 05, 2019

SELL
$151.91 - $192.21 $1.16 Million - $1.47 Million
-7,653 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $1.21 Million - $1.39 Million
7,199 Added 1585.68%
7,653 $1.48 Million
Q2 2018

Aug 02, 2018

SELL
$145.72 - $169.96 $24,918 - $29,063
-171 Reduced 27.36%
454 $77,000
Q1 2018

May 17, 2018

BUY
$151.6 - $177.13 $36,838 - $43,042
243 Added 63.61%
625 $102,000
Q4 2017

Feb 12, 2018

SELL
$137.28 - $155.55 $1.56 Million - $1.77 Million
-11,352 Reduced 96.74%
382 $57,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $1.74 Million - $1.9 Million
11,734
11,734 $1.78 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cibc Private Wealth Group, LLC Portfolio

Follow Cibc Private Wealth Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Private Wealth Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Private Wealth Group, LLC with notifications on news.